A big part of the equation is that FDA would already be familiar with Merck personnel conducting their Trials and would be more receptive to their data, even if it turns out to be bs after the fact.
That of course is in addition to their built in advantage for being part of the "Big Pharma" cabal of corruption.
Unfortunately for us the Buc data may be put under much greater scrutiny as compared to Molnupiravir's.
One huge advantage Buc does have however is it's well documented safety profile when compared to Molnu, where there are already serious concerns about it's potential mutagenic side effect on healthy cells.
Maybe it's time for Revive management/MF to take a page out of Big Pharma's playbook and start playing dirty by highlighting that concerning aspect of Merck's Covid pill since I'm pretty sure the MSM will totally avoid the issue!
News 
Market Data 
Discover 
AI
